Skip to main content
Clinical Trials/NCT07272473
NCT07272473
Recruiting
Not Applicable

Effects of Cervical Mobilization on Dizziness, Balance, and Joint Position Sense in Patients With Meniere's Disease

Abant Izzet Baysal University1 site in 1 country33 target enrollmentStarted: September 20, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
33
Locations
1
Primary Endpoint
Balance assessments

Overview

Brief Summary

The study will employ a stratified randomization method. Patients presenting to the Afyonkarahisar Health Sciences University Health Application and Research Center, Ear, Nose, and Throat Outpatient Clinic, with a definitive diagnosis of Meniere's disease, unilateral or bilateral involvement, and who consent to participate in the study will be divided into three groups. The control group will receive only their routine Betahistine. Their usual treatment will remain unchanged. The first study group will receive 20 minutes of Vestibular Rehabilitation (VR) and 10 minutes of cervical mobilization in addition to their routine Betahistine. The second study group will receive 30 minutes of VR in addition to Betahistine. The study will last 6 weeks. Participants will be assessed using a sociodemographic information questionnaire, the Dizziness Handicap Inventory (DHI), the Vertigo Symptom Scale (VSS), the Neck Disability Index (NDI), the International Tinnitus Inventory (ITI), balance assessment with the K-Force Plates, and joint position sense and proprioception assessment with the Kinvent Physio K-Move. All assessments will be conducted twice, before and after treatment.

Detailed Description

Patients who have been diagnosed with Meniere's disease and who have applied to the Afyonkarahisar Health Sciences University Health Practice and Research Center, Ear, Nose, and Throat Outpatient Clinic will be included in the study.

The study will employ a stratified randomization method. Patients who have been diagnosed with Meniere's disease and have unilateral or bilateral involvement and who agree to participate in the study will be divided into three groups. The control group will only receive their routine Betahistine. Their usual treatments will remain unchanged. The first study group will receive 20 minutes of Vestibular Rehabilitation (VR) and 10 minutes of cervical mobilization in addition to their routine Betahistine. The second study group will receive 30 minutes of VR in addition to Betahistine. The study will last 6 weeks. During the VR sessions:

  1. Adaptation exercises
  2. Habituation exercises
  3. Compensation exercises. A 6-week exercise protocol will be developed. The exercises will gradually increase in difficulty each week. Adaptation exercises will include visual tracking of a moving object while the head is stationary, and tracking objects in different directions while walking. Habituation exercises will include challenging exercises such as coming from lying down to sitting quickly and rising from sitting to standing. Compensation exercises will include walking on surfaces of varying hardness, standing on a balance board, and balancing on a trampoline, each with increasing difficulty each week.

For cervical mobilization, participants will first undergo 3-4 minutes of suboccipital release while lying on their backs to relax, then 2-3 minutes of cervical traction will be applied, and then, while sitting, they will mobilize the C1 and C2 vertebrae using the Mulligan concept.

Participants will be assessed using a sociodemographic questionnaire, the The Dizziness Handicap Inventory (DHI), the Vertigo Symptom Scale (VSS), the Neck Disability Index (NDI), the International Tinnitus Inventory (ITI), balance assessment with the K-Force Plates, and joint position sense and proprioception assessment with the Kinvent Physio K-Move. All assessments will be conducted twice: at baseline and after 6 weeks. This will allow for comparison of the three groups and provide a pre- and post-treatment assessment.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Definitive clinical diagnosis of unilateral or bilateral Meniere's disease
  • Age between 18 and 60 years
  • Presence of fluctuating symptoms or chronic imbalance for at least 3 months
  • Cognitive ability to participate in balance rehabilitation tasks (Mini Mental State Examination score ≥ 24)
  • Willingness to participate in the study and provide informed consent

Exclusion Criteria

  • Diagnosis of vertigo not associated with Meniere's disease
  • Presence of another acute medical condition
  • Neurological, psychological, or cognitive dysfunction
  • History of orthopedic surgery within the last 3 months
  • Planned surgical intervention during the rehabilitation program
  • Cervical spine instability
  • Acute cervical trauma
  • Vertebral artery insufficiency

Outcomes

Primary Outcomes

Balance assessments

Time Frame: From enrollment to the end of treatment at 6 weeks

Balance assessments will be conducted statically and dynamically using K-Force Plates. Both bilateral and unilateral balance tests will be conducted for static balance assessments. In the bilateral balance test, participants will be tested on both feet, first with their eyes open and then with their eyes closed. In the unilateral test, participants will first be asked to stand on their right and left legs for 10 seconds, with their eyes open, and then three repetitions, with the average calculated. They will then be asked to stand on their right and left legs, again, with their eyes closed. In the dynamic balance test, participants will be asked to jump and descend from a step placed 19 cm above the force plate. (Both feet will be suspended before landing.) They will then be asked to balance with their hands on their hips for 15 seconds. If the participant moves their foot or loses their balance completely, the trial will be cancelled and repeated.

Secondary Outcomes

  • Dizziness assesment(From enrollment to the end of treatment at 6 weeks)
  • Vertigo Symptom Assesment(From enrollment to the end of treatment at 6 weeks)
  • Neck Disability Assessment(From enrollment to the end of treatment at 6 weeks)
  • Tinnitus Assessment(From enrollment to the end of treatment at 6 weeks)
  • Proprioception Assessment(From enrollment to the end of treatment at 6 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ömer Osman Pala

ASSOCIATE PROFESSOR

Abant Izzet Baysal University

Study Sites (1)

Loading locations...

Similar Trials